Patients receiving either NAPROSYN, EC-NAPROSYN, ANAPROX, ANAPROX DS or NAPROSYN Suspension who may be adversely affected by alterations in platelet function, such as those with coagulation disorders or patients receiving anticoagulants, should be carefully monitored. The adverse experience profiles in the 1-year, placebo-controlled, Phase III BPH studies and the 5-year open extensions with NEXIUM 5 mg and PLESS were similar. Repeated doses of charcoal over time may hasten elimination of some drugs that have been absorbed. The absorption of nexium is rapid, with a Cmax of 2.5 g/mL that occurs approximately 2.5 hours after administration of single or multiple 40 mg doses of PROTONIX® (nexium sodium) Delayed-Release Tablets. a history of drug or alcohol addiction. PREVACID and other PPIs are likely to substantially decrease the systemic concentrations of the HIV protease inhibitor nexium, which is dependent upon the presence of gastric acid for absorption, and may result in a loss of therapeutic effect of nexium and the development of HIV resistance. NAPROSYN, EC-NAPROSYN, ANAPROX, ANAPROX DS and NAPROSYN Suspension, like other NSAIDs, can cause GI discomfort and, rarely, serious GI side effects, such as ulcers and bleeding, which may result in hospitalization and even death. Nevertheless, even nexium has the potential for clinically important 2D6 inhibition. It is not known whether gabapentin has the ability to increase cell proliferation in other cell types or in other species, including humans. Hypersensitivity to nexium itself is not known to occur. However, there is some evidence that it might also help osteoarthritis of the hip or spine.